By targeting three key growth pathways at once, researchers eliminated pancreatic tumors in multiple mouse models and ...

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...

Explore groundbreaking research on pancreatic cancer treatment that shows promise in inducing complete tumour regression.

Bristol-Myers Squibb (NYSE:BMY) has entered a new collaboration with Microsoft to use AI for earlier lung cancer detection, ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for gedatolisib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA ...

The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...

ImmunityBio Chairman Patrick Soon-Shiong mischaracterized talks with the FDA over the company's cancer drug, sources say.

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...

The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...